First, the FDA provided Merck with a non-approvable letter for Cordaptive. And now the other shoe has fallen – Merck will lay off approximately 20% of its sales force by the summer.
Merck had high hopes that the cholesterol drug Cordaptive could restore the luster to a rather tarnished portfolio. Vytorin has been maligned for safety concerns and unconventional (some say racist) DTC advertising campaign.
The additional 1,200 sales reps that will be loosing their jobs come on top of the 400 reps already eliminated.
Merck had high hopes that the cholesterol drug Cordaptive could restore the luster to a rather tarnished portfolio. Vytorin has been maligned for safety concerns and unconventional (some say racist) DTC advertising campaign.
The additional 1,200 sales reps that will be loosing their jobs come on top of the 400 reps already eliminated.
